Family Health Services offers financial assistance to local patients in Ohio, if their insurance does not pay for GLP-1s or cost is a barrier to access
Mechanism of Action Mounjaro is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonist
Many patients choose a fixed day each week to simplify remembering the dose
After adjusting for residual confounding, the difference in weight loss between those receiving tirzepatide vs semaglutide was 2.0% (95% CI, 2.1% to 1.8%) at 3 months, 3.2% (95% CI, 3.5% to 3.0%) at 6 months, and 5.1% (95% CI, 5.8% to 4.3%) at 12 months
The intake is quiz-based: complete an online health questionnaire, licensed clinician reviews it, and if eligible the prescription ships to your door